Health Funding Opportunities

blog navigation

All Results

blog posts

  • Promoting Research in Basic Neuroscience (R01)

    The goal of this FOA is to stimulate research addressing fundamental questions in basic neuroscience. Proposed projects can address any area of neuroscience within the missions of the participating institutes and should focus on understanding the structure and/or function of the normal nervous system. While fundamental basic research often generates insights relevant to disorders of the nervous system, this FOA is not intended to stimulate research that is explicitly disease-related. Clinical trials are not permitted.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Application Deadline(s): Standard Dates for R01s 2/5/18 through 10/5/20

    FOA

  • Alzheimer's Association Tau Pipeline Enabling Program

    The Alzheimer's Assocation Tau Pipeline Enabling Program (T-PEP) seeks to accelerate the discovery of potential new therapies for tauopathies. The intent of this program is to enrich the pipeline for therapy development by facilitating the translation of academia derived ideas into practical application. In short, it bridges the gap between innovative but resource-constrained researchers and the larger pharmaceutical companies that are looking for drug candidates to be taken into human trials.

    Both non-profit and small for-profit agencies are eligible. Preference will be given to for-profit companies with 50 or fewer employees. For-profits and non-profits must provide documentation verifying status. The PI of the project must be a full-time faculty member or paid employee of the organization submitting the proposal. Applications from post-doctoral researchers will not be accepted.

    Amount: $750,000

    Letter of Intent Deadline: 1/5/18

    Applications submissions are accepted by invitation only.

    FOA

  • NIH Small Research Grant Program (Parent R03)

    The NIH Small Research Grant Program supports small research projects that can be carried out in a short period of time with limited resources. This program supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. This FOA does not accept applications proposing clinical trial(s).

    Amount: Application budgets are limited to $50,000 in direct costs per year

    Application Deadline(s): Standard Dates for R03s 2/16/18 through 10/16/20

    FOA

  • NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22s)

    The NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity Program is designed to enhance the participation of highly trained early career investigators from underrepresented groupsin neuroscience research. These opportunities provide postdoctoral fellows from underrepresented groups with strong training in neuroscience with the resources and tools that will help facilitate a transition to a stable and productive independent research position.

    Applications are sought for the following awards:

    NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22 - Independent Clinical Trial Not Allowed) FOA

    NINDS Advanced Postdoctoral Career Transition Award to Promote Diversity in Neuroscience Research (K22 - Independent Clinical Trial Required) FOA

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, please see FOAs for more details

    Application Deadline(s) (for both opportunities): Standard Dates for K22s 2/12/18 through 10/12/21

    For more information about these opportunities, please click here.

  • Planning Grant to Develop Phase III Clinical Trials for Lewy Body Dementia (R34)

    The purpose of this FOA is to provide one year of support for planning activities necessary for initiating a Phase III clinical trial designed to treat patients with Lewy Body Dementias (LBD), which include Dementia with Lewy Bodies and Parkinson's Disease Dementia. Such activities may include identifying trial sites/collaborators, designing trial protocols and procedures, and addressing regulatory approvals. Clinical trials are not permitted.

    Amount: Application budgets are limited to $150,000 in direct costs over one year.  The amount requested must reflect the actual needs of the proposed project

    Letter of Intent Deadline: 30 days prior to application deadline

    Application Deadline: 3/20/18

    RFP

  • First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01)

    The purpose of this FOA is to encourage cooperative agreement applications to support early stage clinical trials of novel mechanism of action, investigational drugs or drug candidates for the treatment of psychiatric disorders in areas of unmet medical need. The FOA will support milestone-driven early stage trials in pediatric and adult populations. First in human (FIH) and Phase Ib studies of novel Agents must assess target engagement (brain exposure), pharmacological effects, safety, and tolerability to assess feasibility for Phase II/proof of concept (PoC) studies in psychiatric disorders. PoC studies must evaluate the drug’s impact on clinically relevant physiological systems (functional measures) and clinical indicators of effect. The FOA also supports FIH and early feasibility studies (EFS) of novel devices to evaluate target engagement, safety, tolerability, and efficacy. The overall objective is to facilitate rapid collection of data to "de-risk" novel mechanism of action investigational drugs, novel drugs for use in pediatric populations with psychiatric disorders, and devices or combination treatments in order to attract private funding for further clinical development as FDA-approved treatments. A key aspect of this FOA is the formation of collaborative partnerships between the biomedical researchers and biotechnology or industry researchers to facilitate psychiatric drug or device development.

    Clinical trials are required. For pediatric drug trials, the application must include the joint participation of a pediatric pharmacologist and pediatric psychiatrist, as multiple PIs. Additionally, it is required that Contract Research Organizations (CROs) or CTSAs, with expertise in first in pediatric PK/PD bridging studies, will conduct the trial(s). For all other trials that fit the goals of this FOA, it is required that CROs or CTSAs with expertise in the age range and intervention type, conduct the trials.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Letter of Intent Deadline: 30 days prior to application deadline

    Application Deadline(s): Standard Dates for U01s 2/5/18 through 10/5/20

    FOA

  • mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01, R21)

    The purpose of these FOAs, issued by the National Institute of Nursing Research (NINR) and National Institute of Biomedical Imaging and Bioengineering (NIBIB), is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patient–provider communication, adherence to treatment and self-management of chronic diseases in underserved populations. With the rapid expansion of cellular networks and substantial advancements in Smartphone technologies, it is now possible - and affordable - to transmit patient data digitally from remote areas to specialists in urban areas, receive real-time feedback, and capture that consultation in a database. These mHealth tools, therefore, may facilitate more timely and effective patient-provider communication through education communication around goal setting, treatment reminders, feedback on patient progress and may improve health outcomes. These announcements encourage the development, testing and comparative effective analysis of interventions utilizing mHealth technologies. There is also an interest in studying mHealth technologies in underserved populations. NINR and NIBIB seek applications for the following awards:

    - mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R01) RFP

    - mHealth Tools for Individuals with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self-Management (R21) RFP

    For more information about these opportunities, please click here.

  • Collaboratory on Research Definitions for Cognitive Reserve and Resilience to Alzheimer's Disease (R24)

    The purpose of this FOA, issued by the National Institute on Aging (NIA), is to provide infrastructure support to advance development of operational definitions and approaches for the study of the concepts of cognitive reserve and resilience to Alzheimer's disease and related dementias (ADRD) and age-related cognitive decline. The infrastructure support will facilitate a collaborative research network through meetings, conferences, small-scale pilots, and dissemination activities to foster development and champion use of state-of-the-art definitions, uniform nomenclature, and validated approaches that will be key to the advancement of research on maintenance of brain and cognitive health and treatment and/or prevention of ADRD. Clinical trials are not permitted.

    Amount: Application budgets are limited to $500,000 in annual direct costs

    Letter of Intent Deadline: 1/22/18

    Application Deadline: 2/22/18

    RFP

  • NIMH Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3)

    The overall goal of this initiative is to identify neurophysiological measures as potential assays for treatment development research. The FOA will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

    The objectives of the FOA will be accomplished by supporting partnerships among basic and translational neuroscientists who are committed to advancing the discovery of in vivo physiological measures as tools for target validation and therapeutic development. Groups will be tasked with developing and optimizing in vivo assays of brain processes in both animals and in healthy humans. Groups will evaluate assay performance across both species in response to specific chemical, physiological, or behavioral manipulations. In this way, projects will reveal the potential of specific assays to translate from animals to humans, suggesting assays for further development as tools in the treatment development pipeline. Clinical trials are optional.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Letter of Intent Deadline: 30 days prior to the application deadline

    Application Deadline(s): 2/23/18, 6/26/18, 10/24/18

    RFP

  • NIH Pathway to Independence Awards (Parent K99/R00s)

    The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers.

    Applications are sought for the following NIH Pathway to Independence Awards:

    - NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Not Allowed) RFP

    - NIH Pathway to Independence Award (Parent K99/R00 - Independent Clinical Trial Required) RFP

    Application Deadline(s) (for both opportunities): Standard Dates for K99/R00s 2/12/18 through 10/12/20

    For more information about these opportunities, please click here.

  • Development of Socially-Assistive Robots (SARs) to Engage Persons with AD and ADRD, and their Caregivers (R41/R42, R43/R44)

    The National Institute on Aging (NIA) seeks applications for the following awards:

    - Development of Socially-Assistive Robots (SARs) to Engage Persons with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), and their Caregivers (R43/R44) RFP

    - Development of Socially-Assistive Robots (SARs) to Engage Persons with Alzheimer's Disease (AD) and AD-Related Dementias (ADRD), and their Caregivers (R41/R42) RFP

    Amount (for both opportunities): Budgets up to $350,000 total costs per year for Phase I and up to $2,000,000 total costs per year for Phase II may be requested

    Letter of Intent Deadline (for both opportunities): 30 days prior to application deadline

    Application Deadline(s) (for both opportunities): Standard Dates for R41/R42s and R43/R44s 1/5/19 through 4/5/20

    For more information about these opportunities, please click here.

  • Research on Autism Spectrum Disorders (R01, R03, R21)

    Applications are sought for the following awards pertaining to Autism Spectrum Disorders (ASD):

    - Research on Autism Spectrum Disorders (R01) RFP

    - Research on Autism Spectrum Disorders (R03) RFP

    - Research on Autism Spectrum Disorders (R21) RFP

    Note: Clinical trials are optional for all of the above opportunities.

    For more information about these opportunities, please click here.

  • NINDS U01 and P01 Opportunities

    The National Institute of Neurological Disorders and Stroke (NINDS) seeks applications for the following awards:

    - NINDS Efficacy Clinical Trials (U01) RFP

    - NINDS Exploratory Clinical Trials (U01) RFP

    - NINDS Program Project Grant (P01) RFP

    For more information about these opportunities, please click here.

  • Mentored Research Scientist Development Awards (Parent K01s)

    The purpose of these K01 awards is to provide support and “protected time” (three to five years) for an intensive, supervised career development experience in the biomedical, behavioral, or clinical sciences leading to research independence. Although all of the participating NIH Institutes and Centers (ICs) use this support mechanism to support career development experiences that lead to research independence, some ICs use the K01 award for individuals who propose to train in a new field or for individuals who have had a hiatus in their research career because of illness or pressing family circumstances. Other ICs offer separate K01 FOAs intended to increase research workforce diversity.

    Applications are sought for the following awards:

    Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) RFP

    Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) RFP

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, please see RFP for more details

    Application Deadline(s) (for both opportunities): Standard Dates for K01s 2/12/18 through 10/12/20

    For more information about these opportunities, please click here.

  • Independent Scientist Awards (Parent K02s)

    The purpose of these K02 awards is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.

    Applications are sought for the following awards:

    - Independent Scientist Award (Parent K02 - Independent Clinical Trial Not Allowed) RFP

    - Independent Scientist Award (Parent K02 - Independent Clinical Trial Required) RFP

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, please see RFP for more details

    Application Deadline(s) (for both opportunities): Standard Dates for K02s 2/12/18 through 10/12/20

    For more information about these opportunities, please click here.

  • Mentored Clinical Scientist Research Career Development Awards (Parent K08s)

    The purpose of these K08 awards is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

    Applications are sought for the following awards:

    - Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Not Allowed) RFP

    - Mentored Clinical Scientist Research Career Development Award (Parent K08 - Independent Clinical Trial Required) RFP

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, please see RFP for more details

    Application Deadline(s) (for both opportunities): Standard Dates for K08s 2/12/18 through 10/12/20

    For more information about these opportunities, please click here.

  • Mentored Patient-Oriented Research Career Development Awards (Parent K23s)

    The purpose of these K23 awards is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research.

    Applications are sought for the following awards:

    - Mentored Patient-Oriented Research Career Development Award (Parent K23 - Independent Clinical Not Allowed) RFP

    - Mentored Patient-Oriented Research Career Development Award (Parent K23 - Independent Clinical Trial Required) RFP

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, please see RFP for more details

    Application Deadline(s) (for both opportunities): Standard Dates for K23s 2/12/18 through 10/12/20

    For more information about these opportunities, please click here.

  • Kirschstein NRSA Training Grants (Parent T32, Parent T35)

    The National Institutes of Health (NIH) will award Ruth L. Kirschstein National Research Service Award (NRSA) Training Grants (T32 and T35) to eligible, domestic institutions to enhance predoctoral and postdoctoral research training, including short-term research training, and help ensure that a diverse and highly trained workforce is available to meet the needs of the Nation’s biomedical, behavioral, and clinical research agenda.

    Amount (for both opportunities): Application budgets are not limited, but need to reflect the actual needs of the proposed project

    Application Deadline(s) (for both opportunities): Standard Dates for T32s 1/25/18 through 9/25/18; Standard Dates for T35s 1/25/18 through 1/25/21

    For more information about these opportunities, please click here.

  • NMSS Awards

    The National Multiple Sclerosis Society seeks applications for the following awards:

    - Therapeutic Development Opportunities for Neuroprotection and Neuroregeneration in Multiple Sclerosis RFP

    Letter of Intent Deadline: 1/6/18

    - Harry Weaver Neuroscience Scholar Awards RFP

    Letter of Intent Deadline: 8/8/18

    - Collaborative Multiple Sclerosis Research Centers Award RFP

    Letter of Intent Deadline: 8/30/18

    For more information about these opportunities, please click here.

  • Research To Address Sleep Disorders in the Context of Medical Rehabilitation (R01)

    Patients with many disabilities report problems sleeping, but specific sleep disorders are often not diagnosed. Because sleep affects many physiological and behavioral parameters--depression, anxiety, pain, cancer, cardiovascular changes, immune function-- sleep disorders should be diagnosed and appropriately treated to maximize benefit of rehabilitation. Research is needed on ways to best approach this complexity in the context of medical rehabilitation for a primary, non-sleep disorder. Clinical trials are optional. 

    Amount: Application budgets are limited $499,999 or less direct costs per FY and should reflect the actual needs of the proposed project

    Letter of Intent Deadline: 30 days prior to the application deadline

    Application Deadline(s): 3/30/18, 3/29/19

    RFP

  • NINDS Exploratory Neuroscience Research Grant (R21)

    The NINDS Exploratory Neuroscience Research Grant program supports exploratory and innovative research projects, which fall within the mission of the NINDS. Awards will provide support for the early and conceptual stages of projects. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs in the understanding of important areas of neuroscience, or to the development of novel techniques, agents, methodologies, or models, of high value to the neuroscience community. Clinical trials are optional.

    Amount: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year

    Application Deadline(s): Standard Dates for R21s 2/16/18 through 10/16/20

    RFP

  • Zika Virus (ZIKV) Complications (R21)

    The purpose of this FOA is to provide support for research on Zika virus (ZIKV) and its complications. Clinical trials are optional. Note: This FOA replaces PAR-16-106 which had used rolling application due dates to facilitate the rapid review and award of particularly urgent or time-sensitive projects. The last date for submitting an application to PAR-16-106 is January 13, 2017.

    Amount: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year

    Application Deadline(s): Standard Dates for R21s 2/16/18 through 10/16/19

    RFP

  • Mechanistic Basis of Diffuse White Matter Disease and Small Vessel Pathology in Vascular Contributions to Cognitive Impairment and Dementia (R01)

    The purpose of this FOA is to support hypothesis-testing research to elucidate cellular and molecular mechanisms that underlie diffuse white matter disease and small vessel disease in the brain, the relationships between them, and how they may contribute to cognitive impairment and dementia.

    Amount: Application budgets are limited to up to $500,000 direct costs per year, and should reflect the actual needs of the proposed project

    Letter of Intent Deadline: 2/23/18

    Application Deadline: 3/23/18

    RFP

  • Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R01)

    This FOA invites research grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon emission computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Application Deadline(s): Standard Dates for R01s 2/5/18 through 6/5/19

    RFP

  • Imaging - Science Track Award for Research Transition (I/START) (R03)

    This FOA encourages Small Research Grant (R03) applications to facilitate the entry of investigators to the area of neuroimaging, including both new investigators and established investigators seeking to adopt neuroimaging methodologies in their research programs, to enable the conduct of small "proof of concept" studies. The R03 is intended to support research projects that can be carried out in a short period of time with limited resources. Clinical trials are optional.

    To be eligible for an I/START award, a proposed new investigator must be independent of a mentor at the time of award and be at the beginning stages of her/his research career. A proposed new investigator may not have served as the PD/PI on any Public Health-supported research project other than a R03, R15, R21, K01, K08, or K12. Current or past recipients of K02s or K04s are not considered new investigators. Established investigators may also be eligible for support through the I/START program if they are incorporating brain imaging methods for the first time in their research programs.

    Amount: Budgets for direct costs of up to $150,000 per year and is for a period of one year only

    Letter of Intent Deadline: 30 days prior to application deadline

    Application Deadline(s): 2/16/18, 6/16/18

    RFP

  • Advancing Research on Alzheimer's Disease and Alzheimer's-Disease-Related Dementias (R41/R42, R43/R44) )

    These FOAs encourage applications to NIA's Small Business Technology Transfer Research (STTR) program to conduct research leading to the development of innovative products and/or services that may advance progress in preventing and treating Alzheimer's disease (AD) and Alzheimer's-disease-related dementias (ADRD) and/or caring for and treating AD/ADRD patients. Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

    Applications for the following awards are sought:

    - Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R41/R42) RFP

    - Advancing Research on Alzheimer's Disease (AD) and Alzheimer's-Disease-Related Dementias (ADRD) (R43/R44) RFP

    Amount (for both opportunities): According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards.  With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% as a hard cap ($225,000 for Phase I and $1,500,000 for Phase II). However, NIH has received a waiver from SBA, as authorized by statute, to exceed the hard cap of $225,000 for Phase I or $1,500,000 for Phase II for specific topics. The current list of approved topics can be found here.

    Application Deadline(s) (for both opportunities): 1/5/2018, 4/5/2018, 9/5/2018, 1/5/2019, 4/5/2019, 9/5/2019

    For more information about these opportunities, please click here.

  • Mentored Quantitative Research Development Awards (Parent K25s)

    The purpose of these K25 awards is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. Each K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research.

    Applications are sought for the following awards:

    - Mentored Quantitative Research Development Award (Parent K25 - Independent Clinical Not Allowed) RFP

    - Mentored Quantitative Research Development Award (Parent K25 - Independent Clinical Trial Required) RFP

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, please see RFP for more details

    Application Deadline(s) (for both opportunities): Standard Dates for K25s 2/12/18 through 10/12/20

    For more information about these opportunities, please click here.

  • Neuroendocrine Tumor Research Foundation-AACR Grant

    The American Association for Cancer Research seeks applications for the Neuroendocrine Tumor Research Foundation-AACR Grant, representing a joint effort to promote and support innovative cancer research. This grant is available to independent junior and senior investigators to develop and study new ideas and innovative approaches that have direct application and relevance to neuroendocrine tumors. Proposed research may be in any discipline of basic, translational, or clinical cancer research. Applicants must have a doctoral degree (including PhD, MD, DO, DC, ND, DDS, DVM, ScD, DNS, PharmD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree.

    Amount: $250,000

    Application Deadline: 1/9/18

    RFP

  • National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U01, U19)

    NIMH, NIAAA, and NIDA seek applications for the following awards:

    - National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U01) RFP

    - National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental or Substance Use Disorders or Alcohol Addiction (U19) RFP

    The purpose of these FOAs is to accelerate innovative drug and device discovery; develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health, substance use disorders (SUDs) or alcohol addiction; develop and validate tools (pharmacologic or neurostimulation) in support of experimental therapeutic studies of innovative new candidates for mental disorders; and support early stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel Investigational New Drug (IND)-ready agents or Pre-Market Approval (PMA)-ready devices for the treatment of mental disorders, SUDs or alcohol addiction. These FOAs encourage applications to advance the discovery, preclinical development, and proof of concept (PoC) testing of new, rationally based candidate agents and neurostimulation approaches to treat mental disorders or SUDs or alcohol addiction, and to develop novel ligands and circuit-engagement devices as tools to further characterize existing or to validate new drug/device targets. Partnerships between academia and industry are strongly encouraged. These FOAs support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies.

    Amount (for both opportunities): Application budgets are not limited but need to reflect the actual needs of the proposed project

    Letter of Intent Deadline (for both opportunities): 30 days prior to application deadline

    Application Deadline(s) (for both opportunities): Standard Dates for U01s, U19s 2/23/18 through 2/24/20

  • NIA Pathogenesis of Age-Related HIV Neurodegeneration

    NeuroHIV is at an inflection point, with an urgent need to understand the mechanisms that cause and modulate the CNS impairment in the era of antiretroviral therapies. This FOA will encourage basic and clinical research to study commonalities and differences in molecular and cellular mechanisms underpinning neurodegenerative diseases, particularly Alzheimer's disease, and neurological disorders associated with HIV infection and AIDS. In particular, it encourages research to explore the causal role of Alzheimer's disease and other related proteinopathies in HIV-associated neurocognitive disorders in older adults. The funding opportunity envisages cross-disciplinary, multi-PI, and integrative approaches. It will encourage development of both animal and human research to study whether, and how, different neuropathological processes interact with one another, as well as to understand how these interactions lead to neurodegeneration.

    Amount: Application budgets are limited to $500,000 in direct costs per year

    Letter of Intent Deadline: 1/9/18

    Application Deadline: 2/9/18

    RFP

  • NINDS Research Education Programs for Residents and Fellows in Neurological Disorders and Stroke

    NINDS invites applications from institutions/organizations to support programs that provide research education during residency and fellowship designed to prepare clinical residents and fellows for careers as physician-scientists. Participants in the research education program must be residents or fellows. Participants are typically in neurology, neurosurgery or neuropathology residencies and fellowships, but participants may be in any clinical subspecialty residency/fellowship, as long as they are conducting research within the mission of NINDS. Except for the R25 programs that were active in December 2017, only one application per medical school or sponsoring institution will be considered for funding.

    Amount: The total project period for an application submitted in response to this funding opportunity may be up to 5 years. The size of the award will vary among research programs, but applicants must stay within the budgetary guidelines.

    Letter of Intent Deadline: 30 days before application deadline

    Application Deadline(s): 1/23/18, 1/23/19

    RFP

    For more information about this opportunity, please click here.

  • NINDS Faculty Development Awards to Promote Diversity in Neuroscience Research (K01s)

    The purpose of the NINDS Faculty Development Awards to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of award.

    Applications are sought for the following NINDS Faculty Development Awards:

    - NINDS Faculty Development Awards to Promote Diversity in Neuroscience Research (K01- Independent Clinical Trial Not Allowed) FOA

    - NINDS Faculty Development Awards to Promote Diversity in Neuroscience Research (K01 - Clinical Trial Required) FOA

    Amount (for both opportunities): Award budgets are composed of salary and other program-related expenses, as described in the FOA

    Application Deadline(s) (for both opportunities): Standard Dates for K01s 2/12/18 through 10/12/20

    For more information about this opportunity, please click here.

  • PCORI Eugene Washington Engagement Awards

    The Patient-Centered Outcomes Research Institute (PCORI) helps people make informed healthcare decisions and works to improve healthcare delivery and outcomes by producing and promoting high-integrity evidence-based information and research informed by patients, caregivers, and the broader healthcare community. To that end, PCORI is inviting Letters of Inquiry for its Eugene Washington PCORI Engagement Awards program. Through the program, the institute will award grants of up to $250,000 over two years to projects that encourage the active integration of patients, caregivers, clinicians, and other healthcare stakeholders as integral members of the patient-centered outcomes research/clinical effectiveness research (PCOR/CER) enterprise.

    Applications may be submitted by any private or public-sector organization, including any nonprofit or for-profit organization or any unit of local, state, or federal government. All U.S. applicant nonprofit organizations must be recognized by the Internal Revenue Service. Non-domestic components of organizations based in the United States and foreign organizations may apply, as long as there is demonstrable benefit to the U.S. healthcare system and U.S. efforts in the area of patient-centered research can be clearly shown.

    Amount: Up to $250,000 over two years

    Letter of Intent Deadline: 2/1/18

    Application submissions accepted by invitation only.

    RFP

  • Funding for AD Research from Broad Foundation

    The Ruth K. Broad Biomedical Research Foundation, in partnership with Duke University, is accepting applications for the Broad Extramural Award. Through the annual Broad Extramural Award, the foundation will award a two-year grant of up to $180,000 over two years to a non-Duke faculty member in support of research with the potential to advance knowledge of and/or the treatment of Alzheimer's disease. Priority will be given to pilot studies that can lead to more conventional funding. To be eligible, applicants must be a young or established non-Duke investigator proposing new or novel research.

    Amount: Up to $180,000 over 2 years

    Application Deadline: 2/1/18

    RFP

  • NINDS/NIDA Innovation Grants to Nurture Initial Translational Efforts (IGNITE)

    These FOAs, from the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute on Drug Abuse (NIDA), are part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.

    The IGNITE program seeks applications for the following opportunities:

    - Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33) RFP

    Application Deadline: 2/16/18

    - Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33) RFP

    Application Deadline: 2/16/18

    - Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33) RFP

    Application Deadline: 2/16/18

    For more information about these opportunities, please click here.

  • Bioengineering Research (R01, U01)

    Applications are sought for the following opportunities pertaining to bioengineering research:

    - Bioengineering Research Grants (BRG) (R01) RFP

    Application Deadline(s): Standard Dates for R01s 2/5/18 through 2/5/19

    - Bioengineering Research Partnerships (U01) RFP

    Application Deadline(s): 5/8/18; 9/13/18

    For more information about these opportunities, please click here.

  • NIA Alzheimer's Drug-Development Program (U01)

    The goal of this FOA is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization. Clinical trials are optional.

    Amount: Application budgets are limited to $1,000,000 in direct costs per year and need to reflect the actual needs of the proposed project

    Letter of Intent Deadline: 30 days prior to the application deadline

    Application Deadline: 2/5/18

    RFP

  • Mechanisms, Models, Measurement, & Management in Pain Research (R01, R21)

    The purpose of these FOAs is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators. Clinical trials are optional.

    - R01 RFP

    Amount: Application budgets are limited to $1,000,000 in direct costs per year and need to reflect the actual needs of the proposed project

    Application Deadline(s): Standard Dates for R01s 2/5/18 through 2/5/19

    - R21 RFP

    Amount: Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year

    Application Deadline(s): Standard Dates for R21s 2/16/18 through 2/16/19

  • NIMH Exploratory/Developmental Research Grant (R21)

    The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care. Clinical trials are not permitted.

    Amount: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year

    Letter of Intent Deadline: 30 days prior to application deadline

    Application Deadline(s): Standard Dates for R21s 2/16/18 through 10/16/20

    RFP

  • Metabolic Contributions to the Neurocognitive Complications of Diabetes: Ancillary Studies (R01)

    This FOA invites applications for human studies to elucidate the etiology and pathogenesis of the increased risk for neurocognitive impairment associated with type 2 diabetes. Clinical trials are optional.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Application Deadline(s): Standard Dates for R01s 2/5/18 through 6/5/19

    RFP

  • Psychological Health and Traumatic Brain Injury Research Program PSP Translational Research Award

    The DoD FY17 Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP) Peer Support Program (PSP) Translational Research Award seeks applications to support examinations of effectiveness of peer-to-peer support interventions to translate and integrate content into the everyday routines of SMs to enhance psychological health readiness and mitigate negative behavioral health issues including suicide behaviors. Applications should focus on research to evaluate the efficacy and effectiveness of peer support programs that could be implemented in the military. Such interventions should leverage public health paradigms such as the social ecological model, behavior change theory, and adult learning theory. Considerations such as how peer-to-peer support would accommodate military culture, including varied ranks and structure, gender, and occupation requirements should be taken into account. Interventions should be sensitive to the time and contextual constraints associated with occupation and lifestyle. Interventions that include an electronic or virtual component will be considered, but applicants should demonstrate that such components will ensure the interventions are interactive and engaging. Studies should consider ways to integrate content into the everyday routines of SMs to decrease burden and increase buy-in.

    Amount: The anticipated total costs (direct and indirect) budgeted for the entire period of performance will not exceed $3M

    Letter of Intent Deadline: 1/5/18

    Application Deadline: 1/19/18

    RFP

  • Translational Neural Devices (U44, UG3/UH3)

    The National Institute of Neurological Disorders and Stroke (NINDS) seeks applications to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. The translational device activities, including translational bench and animal studies, are expected to lead to submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) or Institutional Review Board (IRB) application for a Non-Significant Risk (NSR) study. These cooperative agreements will also support the subsequent small clinical trial to collect safety and effectiveness data required to support a marketing application or to inform final device design. Please note that clinical trials are required.

    - U44 RFP

    Amount: Applicants should rarely exceed $1,000,000 in total costs per year during the SBIR Phase I and $1,500,000 in total costs per year during the SBIR Phase II

    Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

    - UG3/UH3 RFP

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project. Applicants should rarely exceed $1,000,000 direct costs per year for the UG3 phase and $1,500,000 direct costs per year for the UH3 phase

    Letter of Intent Deadline (for both opportunities): 30 days prior to application deadine

    Application Deadline(s) (for both opportunities): 2/21/18; 6/21/18; 10/22/18; 2/21/19; 6/21/19; 10/21/19; 2/21/20; 6/22/20; 10/21/20

  • BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)

    The purpose of the BRAIN Initiative Fellows (F32) program is to enhance the research training of promising postdoctorates, early in their postdoctoral training period, who have the potential to become productive investigators in research areas that will advance the goals of the BRAIN Initiative. Applications are encouraged in any research area that is aligned with the BRAIN Initiative, including neuroethics. Applicants are expected to propose research training in an area that complements their predoctoral research. Formal training in quantitative perspectives and analytical tools is expected to be an integral part of the proposed research training plan. In order to maximize the training potential of the F32 award, this program encourages applications from individuals who have not yet completed their terminal doctoral degree and who expect to do so within 12 months of the application due date. On the application due date, candidates may not have completed more than 6 months of postdoctoral training.

    Amount: Award budgets are composed of stipends, tuition and fees, and institutional allowance, as described in the RFP

    Letter of Intent Deadline: 30 days prior to application deadline

    Application Deadline(s): Standard Dates for F32s 3/15/18 through 4/7/20

    RFP

    For more information about this opportunity, please click here.

  • Altered neuronal circuits, receptors and networks in HIV-induced Central Nervous System (CNS) dysfunction (R01, R21)

    These FOAs invite research grant applications to decipher pathways and mechanisms responsible for HIV-1 induced central nervous system (CNS) dysfunction seen in virally suppressed HIV-1 positive patients, by understanding the causal role played by altered neuronal circuits, neuronal receptors and neuronal networks. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborative alliances are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the R21  mechanism, while applicants with preliminary data and a discrete, specified, circumscribed project can apply using the R01 mechanism.

    - Research Project Grant (R01) RFP

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    - Exploratory/Developmental Research Grant Award (R21) RFP

    Amount: Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year

    Letter of Intent Deadline (for both opportunities): 30 days prior to application deadline

    Application Deadline (for both opportunities): 1/8/18

  • NSF Developmental Sciences (DS) Program

    Developmental Sciences (DS) supports basic research that increases our understanding of cognitive, linguistic, social, cultural, and biological processes related to human development across the lifespan. Research supported by this program will add to our knowledge of the underlying developmental processes that support social, cognitive, and behavioral functioning, thereby illuminating ways for individuals to live productive lives as members of society.

    Amount: Total cost budget, including both direct and indirect costs, between $100,000 and $200,000 per year

    Letter of Intent Deadline: LOI is not required, but it is often useful for interested applicants to submit (via email) a summary of no more than one page so that the Program Director can advise the investigator on the fit of the project for DS prior to preparation of a full proposal

    Application Deadline: 1/16/18

    RFP

  • NIA Genetics of Alzheimer's Disease Data Storage Site (U24)

    The National Institute on Aging (NIA) invites applications specific to infrastructure that will support storage and analysis of primary and secondary data for the genetics and genomics of Alzheimer's Disease.

    Amount: Direct costs should not exceed $1,000,000 per year

    Letter of Intent Deadline: 30 days prior to application deadline

    Application Deadline(s): Standard Dates for U24s, 1/25/18 through 9/25/18

    RFP

  • NSF Major Research Instrumentation (MRI) Program

    The Major Research Instrumentation (MRI) Program serves to increase access to multi-user scientific and engineering instrumentation for research and research training in our Nation's institutions of higher education and not-for-profit scientific/engineering research organizations. An MRI award supports the acquisition or development of a multi-user research instrument that is, in general, too costly and/or not appropriate for support through other NSF programs. MRI provides support to acquire critical research instrumentation without which advances in fundamental science and engineering research may not otherwise occur. MRI also provides support to develop next-generation research instruments that open new opportunities to advance the frontiers in science and engineering research. Additionally, an MRI award is expected to enhance research training of students who will become the next generation of instrument users, designers and builders.

    The MRI Program seeks broad representation by PIs in its award portfolio, including women, underrepresented minorities and persons with disabilities. Since diversity may be greater among early-career researchers, the MRI program also encourages proposals with early-career PIs and proposals that benefit early-career researchers. The number of MRI proposal submissions allowed per institution continues to be a maximum of three, but is now based on the dollar value of the amount requested from NSF; no more than two submissions are permitted in a newly-defined Track 1 and no more than one submission is permitted in a newly defined Track 2.

    Amount: Track 1 - greater than or equal to $100,0001 and less than $1,000,000; Track 2 - greater than or equal to $1,000,000 up to and including $4,000,000

    Application Deadline(s): 2/5/18; 1/22/19

    RFP

  • Systems Biology Approaches using Non-Mammalian Laboratory Animals to Uncover Causes of Neurodegeneration that Might Underlie ADRD (R01)

    The National Institute on Aging (NIA) is seeking applications on systems biology approaches using non-mammalian laboratory animal models to increase our understanding of the basic biology underpinning neurodegeneration. It is expected that research supported under this FOA will provide new insights into molecular networks that might be involved in causing, amplifying or protecting against neurodegeneration, and that, in turn, might ultimately contribute to Alzheimer's disease or related dementias (ADRD). Importantly, a major goal of this FOA is to use interaction and regulatory networks produced and analyzed using systems biology to gain these new insights. Because this FOA is directed toward discovery, currently employed genetically modified laboratory animals used to study AD are not required, although they may be used. Because this FOA requires systems biology approaches, data used to build interaction or regulatory networks may also come from humans or other mammals in which AD, related dementias, or aging-related cognitive decline have been observed. This FOA will only support studies using non-mammalian laboratory animal models; studies involving humans or experiments with mammals will not be allowed under this FOA. Clinical trials are not permitted.

    Amount: Application budgets are not limited but need to reflect the actual needs of the proposed project

    Letter of Intent Deadline: 1/21/18

    Application Deadline: 2/21/18

    RFP

  • NIH Blue Print: Development and Validation of Technologies for Rapid Isolation and Characterization of Extracellular Vesicles of Central Nervous System Origin (R21/R33)

    This FOA encourages applications that will develop novel technologies and/or tools for the isolation and characterization of extracellular vesicles (EVs) of Central Nervous System (CNS) origin. The primary focus of the technology development includes robust and reproducible CNS-EV isolation methods. Specifically, there is a need to establish technologies for the isolation and purification of CNS-EVs from peripheral samples and the characterization of CNS-EV types, cargos, and origin, as well as to validate these methods for further analyses. Validation of these technologies may include the analysis of the full range of EV composition such as RNA, proteins, lipids, and metabolites. Clinical trials are not permitted.

    Amount: For the R21 phase, the combined budget for direct costs for a two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year. For the R33 phase, application budgets may not exceed $500,000 in annual direct costs.

    Letter of Intent Deadline: 12/22/17

    Application Deadline: 1/22/18

    RFP

  • CURE Award for Investigator-Initiated Epilepsy Research

    Citizens United for Research in Epilepsy (CURE) prioritizes highly innovative, risky, paradigm-shifting projects that address CURE’s mission to cure epilepsy, affirming our core belief that the only acceptable final goal is “no seizures, no side-effects.” CURE's investigator-initiated grants program seeks to push the envelope and accelerate promising research leading to disease-modifying breakthroughs for people living with epilepsy. This award is available to both established and early career investigators.

    Amount: $250,000

    Letter of Intent Deadline: 3/18/18

    Application submissions accepted by invitation only.

    RFP